A recent study by Zhang and colleagues found that PACMP, a lncRNA-derived micropeptide, is an activator that promotes PARP1-meidiated PARylation, and PACMP inhibition renders sensitivity of cancer cells to diverse chemo- and targeted therapies (Zhang et al., 2022). Here, PARP1 is linked to cancer.